Ultragenyx Pharma (RARE) Reports Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase Deficiency
Tweet Send to a Friend
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced positive interim safety and efficacy data from the first dose cohort of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
